Use of topical corticosteroids and topical calcineurin inhibitors for the treatment of atopic dermatitis in thin and sensitive skin areas

被引:43
作者
Draelos, Zoe D. [1 ]
机构
[1] Wake Forest Univ, Sch Med, Winston Salem, NC 27109 USA
关键词
atopic dermatitis; calcineurin inhibitors; corticosteroids; pimecrolimus; sensitive; skin; tacrolimus;
D O I
10.1185/030079908X280419
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background.-Atopic dermatitis (AD) is a common, chronic skin disorder characterized by itch and dry skin, which can develop into pruritic red plaques that ooze when scratched. AD flares often occur in anatomic areas where the skin is naturally thin (the face, neck, and intertriginous zones). Such regions, especially the face, are also areas of sensitive skin and need special consideration when being treated. Objective: This article will briefly review the concepts of thin and sensitive skin and discuss the treatment of AD in such areas. Methods: The MEDLINE database was searched for English-language articles published that contained the text terms atopic dermatitis, sensitive skin, treatment, topical corticosteroids, or topical calcineurin inhibitors. Articles that pertained to the safety and efficacy of various treatments were selected for further review. Results: Topical corticosteroids (TCSs) are effective for the treatment of AD in thin and sensitive skin areas, but their use is limited due to adverse events, such as skin thinning, and the potential for impairing the skin barrier. Topical calcineurin inhibitors (TCls) also provide effective AD treatment without impairing the skin barrier or inducing skin thinning. Although TCls may be associated with a higher incidence of applicationsite reactions such as pruritus and skin burning, these symptoms are typically transient and mild to moderate in nature. Limitations: This analysis focused primarily on relatively recent key trials evaluating the treatment of AD in sensitive skin; due to the limited number of controlled trials evaluating TCS agents, consensus statements and comprehensive review articles were used for most of the information pertaining to this therapeutic option. Conclusions: Although both TCSs and TCls have a place in a long-term, comprehensive treatment strategy for AD, TCls may have a particular use in thin and sensitive skin areas.
引用
收藏
页码:985 / 994
页数:10
相关论文
共 80 条
  • [1] Systemic exposure, tolerability, and efficacy of pimecrolimus cream 1% in atopic dermatitis patients
    Allen, BR
    Lakhanpaul, M
    Morris, A
    Lateo, S
    Davies, T
    Scott, G
    Cardno, M
    Ebelin, ME
    Burtin, P
    Stephenson, TJ
    [J]. ARCHIVES OF DISEASE IN CHILDHOOD, 2003, 88 (11) : 969 - 973
  • [2] Efficacy and tolerability of topical pimecrolimus and tacrolimus in the treatment of atopic dermatitis: meta-analysis of randomised controlled trials
    Ashcroft, DM
    Dimmock, P
    Garside, R
    Stein, K
    Williams, HC
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 2005, 330 (7490): : 516 - 522
  • [3] *AST PHARM US INC, 2006, PROT PRESCR INF
  • [4] The use of topical calcineurin inhibitors in dermatology: Safety concerns - Report of the American Academy of Dermatology Association Task Force
    Berger, TG
    Duvic, M
    Van Voorhees, AS
    Frieden, IJ
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2006, 54 (05) : 818 - 823
  • [5] Percutaneous absorption of drugs used in atopic eczema:: pimecrolimus permeates less through skin than corticosteroids and tacrolimus
    Billich, A
    Aschauer, H
    Aszódi, A
    Stuetz, A
    [J]. INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2004, 269 (01) : 29 - 35
  • [6] A randomized, vehicle-controlled trial of tacrolimus ointment for treatment of atopic dermatitis in children
    Boguniewicz, M
    Fiedler, VC
    Raimer, S
    Lawrence, ID
    Leung, DYM
    Hanifin, JM
    [J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 1998, 102 (04) : 637 - 644
  • [7] Safety and efficacy of topical calcineurin inhibitors in the treatment of childhood atopic dermatitis
    Breuer, K
    Werfel, T
    Kapp, A
    [J]. AMERICAN JOURNAL OF CLINICAL DERMATOLOGY, 2005, 6 (02) : 65 - 77
  • [8] Influence of pimecrolimus cream 1% on different morphological signs of eczema in infants with atopic dermatitis
    Breuer, K
    Braeutigam, M
    Kapp, A
    Werfel, T
    [J]. DERMATOLOGY, 2004, 209 (04) : 314 - 320
  • [9] A systematic review of the safety of topical therapies for atopic dermatitis
    Callen, J.
    Chamlin, S.
    Eichenfield, L. F.
    Ellis, C.
    Girardi, M.
    Goldfarb, M.
    Hanifin, J.
    Lee, P.
    Margolis, D.
    Paller, A. S.
    Piacquadio, D.
    Peterson, W.
    Kaulback, K.
    Fennerty, M.
    Wintroub, B. U.
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2007, 156 (02) : 203 - 221
  • [10] *CER CORP, 2006, EP SKIN BARR EM 510